

# Joao Goncalves

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2991423/publications.pdf>

Version: 2024-02-01

141  
papers

5,163  
citations

101543

36  
h-index

102487

66  
g-index

149  
all docs

149  
docs citations

149  
times ranked

7159  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface. <i>Cell</i> , 2015, 163, 1484-1499.	28.9	446
2	Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. <i>Genes and Development</i> , 2004, 18, 2861-2866.	5.9	259
3	Identification of SOX3 as an XX male sex reversal gene in mice and humans. <i>Journal of Clinical Investigation</i> , 2011, 121, 328-341.	8.2	234
4	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174.	0.9	173
5	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
6	High frequency of DAZ1/DAZ2 gene deletions in patients with severe oligozoospermia. <i>Molecular Human Reproduction</i> , 2002, 8, 286-298.	2.8	153
7	The Ciliary Transition Zone: Finding the Pieces and Assembling the Gate. <i>Molecules and Cells</i> , 2017, 40, 243-253.	2.6	145
8	Subcellular localization of the Vif protein of human immunodeficiency virus type 1. <i>Journal of Virology</i> , 1994, 68, 704-712.	3.4	138
9	Incorrect DNA methylation of the DAZL promoter CpG island associates with defective human sperm. <i>Human Reproduction</i> , 2010, 25, 2647-2654.	0.9	135
10	The AZFc region of the Y chromosome: at the crossroads between genetic diversity and male infertility. <i>Human Reproduction Update</i> , 2010, 16, 525-542.	10.8	122
11	Human Spermatogenic Failure Purges Deleterious Mutation Load from the Autosomes and Both Sex Chromosomes, including the Gene DMRT1. <i>PLoS Genetics</i> , 2013, 9, e1003349.	3.5	118
12	Role of Vif in human immunodeficiency virus type 1 reverse transcription. <i>Journal of Virology</i> , 1996, 70, 8701-8709.	3.4	118
13	Global Interactomics Uncovers Extensive Organellar Targeting by Zika Virus. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2242-2255.	3.8	112
14	Phosphorylation of Vif and Its Role in HIV-1 Replication. <i>Journal of Biological Chemistry</i> , 1996, 271, 10121-10129.	3.4	103
15	Ultrastructure of HIV-1 Genomic RNA. <i>Virology</i> , 1997, 233, 271-279.	2.4	96
16	Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds. <i>Free Radical Biology and Medicine</i> , 2014, 73, 95-105.	2.9	85
17	Camelized Rabbit-derived VH Single-domain Intrabodies Against Vif Strongly Neutralize HIV-1 Infectivity. <i>Journal of Molecular Biology</i> , 2004, 340, 525-542.	4.2	81
18	HIV-1 Vif Can Directly Inhibit Apolipoprotein B mRNA-editing Enzyme Catalytic Polypeptide-like 3G-mediated Cytidine Deamination by Using a Single Amino Acid Interaction and Without Protein Degradation. <i>Journal of Biological Chemistry</i> , 2005, 280, 8765-8775.	3.4	78

#	ARTICLE	IF	CITATIONS
19	Attenuation of HIV-1 Replication in Primary Human Cells with a Designed Zinc Finger Transcription Factor. <i>Journal of Biological Chemistry</i> , 2004, 279, 14509-14519.	3.4	77
20	Catechols from abietic acid. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 1631-1638.	3.0	76
21	Genetic Dissection of the AZF Regions of the Human Y Chromosome: Thriller or Filler for Male (In)fertility?. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-18.	3.0	74
22	Spatial and proteomic profiling reveals centrosome-independent features of centriolar satellites. <i>EMBO Journal</i> , 2019, 38, e101109.	7.8	73
23	Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. <i>Journal of Virology</i> , 1995, 69, 7196-7204.	3.4	69
24	Functional Neutralization of HIV-1 Vif Protein by Intracellular Immunization Inhibits Reverse Transcription and Viral Replication. <i>Journal of Biological Chemistry</i> , 2002, 277, 32036-32045.	3.4	68
25	Era of biosimilars in rheumatology: reshaping the healthcare environment. <i>RMD Open</i> , 2019, 5, e000900.	3.8	67
26	No Evidence for an mtDNA Role in Sperm Motility: Data from Complete Sequencing of Asthenozoospermic Males. <i>Molecular Biology and Evolution</i> , 2007, 24, 868-874.	8.9	60
27	Recombinant Antibodies as Therapeutic Agents. <i>BioDrugs</i> , 2008, 22, 301-314.	4.6	57
28	Characterization of plasma labile heme in hemolytic conditions. <i>FEBS Journal</i> , 2017, 284, 3278-3301.	4.7	55
29	Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands. <i>Drug Discovery Today</i> , 2019, 24, 1985-2001.	6.4	52
30	TBCCD1, a new centrosomal protein, is required for centrosome and Golgi apparatus positioning. <i>EMBO Reports</i> , 2010, 11, 194-200.	4.5	50
31	Inhibition of Human Immunodeficiency Virus Type 1 Replication with Artificial Transcription Factors Targeting the Highly Conserved Primer-Binding Site. <i>Journal of Virology</i> , 2006, 80, 2873-2883.	3.4	49
32	Functional Analysis of Vif Protein Shows Less Restriction of Human Immunodeficiency Virus Type 2 by APOBEC3G. <i>Journal of Virology</i> , 2005, 79, 823-833.	3.4	46
33	Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. <i>Frontiers in Immunology</i> , 2013, 4, 343.	4.8	45
34	Immunogenicity of biologic agents in rheumatology. <i>Nature Reviews Rheumatology</i> , 2021, 17, 81-97.	8.0	43
35	Tubulin cofactor A gene silencing in mammalian cells induces changes in microtubule cytoskeleton, cell cycle arrest and cell death. <i>FEBS Letters</i> , 2005, 579, 3515-3524.	2.8	42
36	Novel promoter and splice junction defects add to the genetic, clinical or geographic heterogeneity of $\beta$ -thalassaemia in the Portuguese population. <i>Human Genetics</i> , 1992, 89, 573-6.	3.8	40

#	ARTICLE	IF	CITATIONS
37	A de novo paradigm for male infertility. <i>Nature Communications</i> , 2022, 13, 154.	12.8	38
38	Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. <i>Rheumatology and Therapy</i> , 2020, 7, 741-757.	2.3	37
39	Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. <i>Scientific Reports</i> , 2017, 7, 45647.	3.3	36
40	Sulfated Polysaccharides in Marine Sponges: Extraction Methods and Anti-HIV Activity. <i>Marine Drugs</i> , 2011, 9, 139-153.	4.6	35
41	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020, 34, 27-37.	4.6	35
42	Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells. <i>Blood</i> , 2005, 106, 3797-3802.	1.4	34
43	Mob1: defining cell polarity for proper cell division. <i>Journal of Cell Science</i> , 2012, 125, 516-527.	2.0	34
44	Cilia Distal Domain: Diversity in Evolutionarily Conserved Structures. <i>Cells</i> , 2019, 8, 160.	4.1	34
45	Cell Type-Specific Targeting with Sindbis Pseudotyped Lentiviral Vectors Displaying Anti-CCR5 Single-Chain Antibodies. <i>Human Gene Therapy</i> , 2005, 16, 223-234.	2.7	32
46	miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication. <i>EMBO Journal</i> , 2017, 36, 346-360.	7.8	32
47	Novel HIV-1 Knockdown Targets Identified by an Enriched Kinases/Phosphatases shRNA Library Using a Long-Term Iterative Screen in Jurkat T-Cells. <i>PLoS ONE</i> , 2010, 5, e9276.	2.5	31
48	Characterizing partial AZFc deletions of the Y chromosome with amplicon-specific sequence markers. <i>BMC Genomics</i> , 2007, 8, 342.	2.8	30
49	Human mtDNA haplogroups and reduced male fertility: real association or hidden population substructuring. <i>Journal of Developmental and Physical Disabilities</i> , 2005, 28, 241-247.	3.6	29
50	The Expression of Tubulin Cofactor A (TBCA) Is Regulated by a Noncoding Antisense TbcA RNA during Testis Maturation. <i>PLoS ONE</i> , 2012, 7, e42536.	2.5	29
51	Modular Assembly of Reversible Multivalent Cancer-Targeting Drug Conjugates. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 9346-9350.	13.8	29
52	Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?. <i>Current Rheumatology Reports</i> , 2016, 18, 50.	4.7	27
53	HIV-1 Vif and APOBEC3G: multiple roads to one goal. <i>Retrovirology</i> , 2004, 1, 28.	2.0	26
54	Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. <i>Journal of Dermatological Treatment</i> , 2020, 31, 794-800.	2.2	26

#	ARTICLE	IF	CITATIONS
55	Piezoelectric biosensors for biorecognition analysis: Application to the kinetic study of HIV-1 Vif protein binding to recombinant antibodies. <i>Journal of Biotechnology</i> , 2007, 132, 142-148.	3.8	25
56	Mutation C11994T in the mitochondrial ND4 gene is not a cause of low sperm motility in Portugal. <i>Fertility and Sterility</i> , 2008, 89, 738-741.	1.0	25
57	The biosimilar approval process: how different is it?. <i>Considerations in Medicine</i> , 2017, 1, 3-6.	0.0	25
58	LUZP1 and the tumor suppressor EPLIN modulate actin stability to restrict primary cilia formation. <i>Journal of Cell Biology</i> , 2020, 219, .	5.2	25
59	The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 28586-28598.	1.8	24
60	HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. <i>Molecular Immunology</i> , 2007, 44, 583-590.	2.2	22
61	Î²-Thalassaemia unlinked to the Î²-globin gene interacts with sickle-cell trait in a Portuguese family. <i>British Journal of Haematology</i> , 1995, 91, 85-89.	2.5	20
62	Autoinhibition of TBCB regulates EB1-mediated microtubule dynamics. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 357-371.	5.4	20
63	Antigenic response to <sc>CT</sc>â€P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 507-522.	3.7	20
64	The Portuguese Society of Rheumatology position paper on the use of biosimilars. <i>Acta ReumatolÃ³gica Portuguesa</i> , 2014, 39, 60-71.	0.2	20
65	Therapeutic Antibody Engineering and Selection Strategies. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2019, 171, 55-86.	1.1	19
66	Recombinant single-chain variable fragment and single domain antibody piezoimmunosensors for detection of HIV1 virion infectivity factor. <i>Biosensors and Bioelectronics</i> , 2007, 23, 384-392.	10.1	18
67	A novel Alu-mediated microdeletion at 11p13 removes WT1 in a patient with cryptorchidism and azoospermia. <i>Reproductive BioMedicine Online</i> , 2014, 29, 388-391.	2.4	18
68	Biosimilars: considerations for clinical practice. <i>Considerations in Medicine</i> , 2017, 1, 13-18.	0.0	18
69	Rare double sex and mab-3-related transcription factor 1 regulatory variants in severe spermatogenic failure. <i>Andrology</i> , 2015, 3, 825-833.	3.5	17
70	Importation route of the sickle cell trait into Portugal: contribution of molecular epidemiology. <i>Human Biology</i> , 1992, 64, 891-901.	0.2	17
71	Biodistribution of a <sup>67</sup> Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain (Zag). <i>Nuclear Medicine and Biology</i> , 2014, 41, e44-e48.	0.6	16
72	Is prnt a Pseudogene? Identification of Ram Prt in Testis and Ejaculated Spermatozoa. <i>PLoS ONE</i> , 2012, 7, e42957.	2.5	16

#	ARTICLE	IF	CITATIONS
73	Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins. Journal of Biotechnology, 2017, 253, 23-33.	3.8	14
74	Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody. Cellular and Molecular Life Sciences, 2020, 77, 2859-2870.	5.4	14
75	Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. Aids, 2016, 30, 1691-1701.	2.2	12
76	Next-generation sequencing of hereditary hemochromatosis-related genes: Novel likely pathogenic variants found in the Portuguese population. Blood Cells, Molecules, and Diseases, 2016, 61, 10-15.	1.4	12
77	Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies. Scientific Reports, 2018, 8, 7450.	3.3	12
78	Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication. Biotechnology and Applied Biochemistry, 2012, 59, 353-366.	3.1	11
79	Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display. Arthritis Research and Therapy, 2015, 17, 168.	3.5	11
80	The Mutational Spectrum of <i>WT1</i> in Male Infertility. Journal of Urology, 2015, 193, 1709-1715.	0.4	11
81	CIB1 and CIB2 are HIV-1 helper factors involved in viral entry. Scientific Reports, 2016, 6, 30927.	3.3	11
82	Biosimilar DMARDs: What Does the Future Hold?. Drugs, 2016, 76, 629-637.	10.9	11
83	Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads. Advances in Protein Chemistry and Structural Biology, 2018, 112, 143-182.	2.3	11
84	SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989108.	3.2	11
85	Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Targeted Oncology, 2020, 15, 467-475.	3.6	11
86	The NEMP family supports metazoan fertility and nuclear envelope stiffness. Science Advances, 2020, 6, eabb4591.	10.3	11
87	Biosimilar monoclonal antibodies: preclinical and clinical development aspects. Clinical and Experimental Rheumatology, 2016, 34, 698-705.	0.8	11
88	Revisiting the tubulin folding pathway: new roles in centrosomes and cilia. Biomolecular Concepts, 2010, 1, 423-434.	2.2	10
89	A novel reactive epitope-based antigen targeted by serum autoantibodies in oligoarticular and polyarticular juvenile idiopathic arthritis and development of an electrochemical biosensor. Immunobiology, 2016, 221, 634-640.	1.9	10
90	M13 bacteriophage purification using poly(ionic liquids) as alternative separation matrices. Journal of Chromatography A, 2018, 1532, 246-250.	3.7	10

#	ARTICLE	IF	CITATIONS
91	Celastrol Efficacy by Oral Administration in the Adjuvant-Induced Arthritis Model. <i>Frontiers in Medicine</i> , 2020, 7, 455.	2.6	10
92	Integrated in Silico and Experimental Approach towards the Design of a Novel Recombinant Protein Containing an Anti-HER2 scFv. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3547.	4.1	10
93	Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors. <i>PLoS ONE</i> , 2016, 11, e0150037.	2.5	10
94	Evaluation of Male Fertility-Associated Loci in a European Population of Patients with Severe Spermatogenic Impairment. <i>Journal of Personalized Medicine</i> , 2021, 11, 22.	2.5	10
95	Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening. <i>Pharmaceutics</i> , 2021, 13, 1598.	4.5	10
96	Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 151-6.	2.3	9
97	Besnoitia besnoiti and Toxoplasma gondii: two apicomplexan strategies to manipulate the host cell centrosome and Golgi apparatus. <i>Parasitology</i> , 2014, 141, 1436-1454.	1.5	9
98	Anti-type II collagen antibodies detection and avidity in patients with oligoarticular and polyarticular forms of juvenile idiopathic arthritis. <i>Immunology Letters</i> , 2015, 165, 20-25.	2.5	9
99	Biosimilars in rheumatology. <i>Pharmacological Research</i> , 2019, 149, 104467.	7.1	8
100	Pharmacology of biosimilar candidate drugs in rheumatology: a literature review. <i>Acta Reumatológica Portuguesa</i> , 2014, 39, 19-26.	0.2	8
101	AB0096â€¦Efficacy and safety of oral administration of pure celastrol in aia rats. , 2017, , .		7
102	Molecular construction of bionanoparticles: chimaeric SIV p17â€“HIV I p6 nanoparticles with minimal viral protein content. <i>Biotechnology and Applied Biochemistry</i> , 2007, 48, 35.	3.1	6
103	Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target?. <i>Advances in Virology</i> , 2010, 2010, 1-10.	1.1	6
104	Modular Assembly of Reversible Multivalent Cancerâ€“Cellâ€“Targeting Drug Conjugates. <i>Angewandte Chemie</i> , 2017, 129, 9474-9478.	2.0	6
105	Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 649-661.	4.7	6
106	Widening the spectrum of deletions and molecular mechanisms underlying alpha-thalassemia. <i>Annals of Hematology</i> , 2017, 96, 1921-1929.	1.8	6
107	Biosimilars already approved and in development. <i>Considerations in Medicine</i> , 2017, 1, 7-12.	0.0	6
108	Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies. <i>PLoS ONE</i> , 2018, 13, e0208147.	2.5	6

#	ARTICLE	IF	CITATIONS
109	HIV-1 Vif Interaction with APOBEC3 Deaminases and its Characterization by a New Sensitive Assay. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 296-307.	4.1	5
110	Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically. <i>BioDrugs</i> , 2019, 33, 683-691.	4.6	5
111	Magnetic Precipitation: A New Platform for Protein Purification. <i>Biotechnology Journal</i> , 2020, 15, 2000151.	3.5	5
112	A purification platform for antibodies and derived fragments using a de novo designed affinity adsorbent. <i>Separation and Purification Technology</i> , 2021, 265, 118476.	7.9	5
113	Origin, phylogeny, variability and epitope conservation of SARS-CoV-2 worldwide. <i>Virus Research</i> , 2021, 304, 198526.	2.2	5
114	Biosimilars in an era of rising oncology treatment options. <i>Future Oncology</i> , 2021, 17, 3881-3892.	2.4	5
115	A novel mosaic Bantu/Benin/Bantu $\hat{I}^2$ s haplotype found in several African populations. <i>Human Genetics</i> , 1994, 94, 101-103.	3.8	4
116	Camphor-based CCR5 blocker lead compounds – a computational and experimental approach. <i>RSC Advances</i> , 2016, 6, 56249-56259.	3.6	4
117	Tetrahymena Cilia Cap is Built in a Multi-step Process: A Study by Atomic Force Microscopy. <i>Protist</i> , 2017, 168, 697-717.	1.5	4
118	Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 239-243.	1.5	4
119	Assessing combinatorial strategies to multimerize libraries of single-domain antibodies. <i>Biotechnology and Applied Biochemistry</i> , 2012, 59, 193-204.	3.1	3
120	The hepcidin gene promoter nc.-1010C > T; $\hat{A}^{\sim}582A$ > G haplotype modulates serum ferritin in individuals carrying the common H63D mutation in HFE gene. <i>Annals of Hematology</i> , 2014, 93, 2063-2066.	1.8	3
121	Insights on the Formulation of Recombinant Proteins. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2019, 171, 23-54.	1.1	3
122	Protein Delivery of Cell-Penetrating Zinc-Finger Activators Stimulates Latent HIV-1-Infected Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 145-158.	4.1	3
123	Anti-HIV-1 Activity of pepRF1, a Proteolysis-Resistant CXCR4 Antagonist Derived from Dengue Virus Capsid Protein. <i>ACS Infectious Diseases</i> , 2021, 7, 6-22.	3.8	3
124	APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner. <i>Journal of Virology</i> , 2021, 95, e0117021.	3.4	3
125	Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 2501-2512.	3.6	3
126	Ubiquitin-fusion as a strategy to modulate protein half-life: A3G antiviral activity revisited. <i>Virology</i> , 2009, 393, 286-294.	2.4	2



#	ARTICLE	IF	CITATIONS
127	Screening polymeric ionic liquids for chromatography-based purification of bacteriophage M13. Separation and Purification Technology, 2021, 257, 117906.	7.9	2
128	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. BioDrugs, 2021, 35, 35-45.	4.6	2
129	KSHV Latency in Transformed B-cells: The Role of LANA1 as a Therapeutic Target. Virology: Research and Treatment, 2008, 1, VRT.S631.	3.5	1
130	Methods and cell-based strategies to produce antibody libraries: current state. Applied Microbiology and Biotechnology, 2021, 105, 7215-7224.	3.6	1
131	Camelized Rabbit-derived VH Single-domain Intrabodies Against Vif Strongly Neutralize HIV-1 Infectivity. Journal of Mathematical Analysis and Applications, 2004, 294, 525-525.	1.0	0
132	Cell-based Assay for Testing Susceptibility of HIV-1 to Protease Inhibitors. Retrovirology, 2005, 2, P140.	2.0	0
133	Intrabody-based Mapping of Latency-associated Nuclear Antigen from Kaposi's Sarcoma-associated Herpesvirus Show Conserved Epitopes for Viral Latency Inhibition. Virology: Research and Treatment, 2010, 2, VRT.S975.	3.5	0
134	SAT0160â€¦Immunogenicity of biosimilars for the treatment of inflammatory rheumatic diseases: a review from confirmatory clinical trials. , 2017, , .		0
135	SAT0046â€¦TNF antagonist drug safety assessment by pharmacovigilance signaling and post-marketing adverse event reports. , 2017, , .		0
136	Considering biosimilar policy. Considerations in Medicine, 2017, 1, 19-24.	0.0	0
137	AB0473â€¦Immunogenicity of biosimilars for rheumatic diseases: an updated review from regulatory documents and confirmatory clinical trials. , 2018, , .		0
138	Editorial: antigenic response to <sc>CT</sc>â€”P13 and infliximab originator in <sc>IBD</sc> shows similar epitope recognitionâ€”evidence from basic science supports safe switching to biosimilars. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 575-576.	3.7	0
139	P664 SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis. Journal of Crohn's and Colitis, 2019, 13, S451-S452.	1.3	0
140	Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity. BioDrugs, 2019, 33, 693-695.	4.6	0
141	FRI0663â€¦The fine specificity of anti-drug antibody responses to originator and biosimilar infliximab: analyses across five diseases from the 52-week randomized nor-switch study. , 2018, , .		0